Martin Reck, MD, PhD, from the Lung Clinic Grosshansdorf, Grosshansdorf, Germany talks to us about the JAVELIN lung 100 study (NCT02576574), an ongoing Phase III clinical trial which compares the efficacy of avelumab against platinum-based chemotherapy in the treatment of patients with non-small cell lung cancer. Prof. Reck discusses how the trial is being conducted and the ways in which the trial has evolved, and explains how patients may benefit from its data. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) held in Madrid, Spain.